177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

ClinicalTrials.gov Identifier: NCT04689828

Novartis Reference Number: CAAA617B12302

Last Update: May 09, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The purpose of this study is to determine whether 177Lu-PSMA-617 improves the rPFS or death compared to a change in ARDT in mCRPC participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings.

Approximately 450 participants will be randomized (225 per treatment group).

Condition 
Prostatic Neoplasms
Phase 
Phase 3
Overall status 
Recruiting
Start date 
Jun 15, 2021
Completion date 
Aug 03, 2023
Gender 
Male
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Drug
177Lu-PSMA-617
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Drug
68Ga-PSMA-11
single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
Drug
ARDT
administered orally on a continuous basis, as per package insert and guidelines
Other
Best supportive care
Best supportive/best standard of care as defined by the local investigator
Drug
177Lu-PSMA-617
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Drug
68Ga-PSMA-11
single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
Drug
ARDT
administered orally on a continuous basis, as per package insert and guidelines
Other
Best supportive care
Best supportive/best standard of care as defined by the local investigator
Drug
177Lu-PSMA-617
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Drug
68Ga-PSMA-11
single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
Drug
ARDT
administered orally on a continuous basis, as per package insert and guidelines
Other
Best supportive care
Best supportive/best standard of care as defined by the local investigator

Eligibility Criteria

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

Signed informed consent must be obtained prior to participation in the study
Participants must be adults ≥ 18 years of age
Participants must have an ECOG performance status of 0 to 1
Participants must have histological pathological, and/or cytological confirmation of adenocarcinoma of the prostate
Participants must be 68Ga-PSMA-11 PET/CT scan positive, and eligible as determined by the sponsor's central reader
Participants must have a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L)

Participants must have progressed only once on prior second generation ARDT (abiraterone, enzalutamide, darolutamide, or apalutamide)

first generation androgen receptor inhibitor therapy (e.g. bicalutamide) is allowed but not considered as prior AEDT therapy
second generation ARDT must be the most recent therapy received

Participants must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:

Serum/plasma PSA progression defined as 2 increases in PSA measured at least 1 week apart. The minimal start value is 2.0 ng/mL. 1.0 ng/ml is the minimal starting value if confirmed rise in PSA is the only indication of progression.
Soft-tissue progression defined [PCWG3-modified RECIST v1.1 (Eisenhauer et al 2009, Scher et al 2016)]
Progression of bone disease two new lesions only positivity on the bone scan defines metastatic disease to bone (PCWG3 criteria (Scher et al 2016))
Participants must have ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained prior to randomization.
Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia

Participants must have adequate organ function:

Bone marrow reserve:
ANC ≥ 1.5 x 109/L
Platelets ≥100 x 109/L
Hemoglobin ≥ 9 g/dL
Hepatic:
Total bilirubin < 2 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤ 3 x ULN is permitted
ALT or AST ≤ 3.0 x ULN OR ≤ 5.0 x ULN for participants with liver metastases
Renal:
eGFR ≥ 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation
Albumin ≥ 2.5 g/dL
Candidates for change in ARDT as assessed by the treating physician • Participants cannot have previously progressed nor had intolerable toxicity to both enzalutamide and abiraterone.

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study:

Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
Previous PSMA-targeted radioligand therapy
Prior treatment with PARP inhibitors, cytotoxic chemotherapy for castration resistant or castrate sensitive prostate cancer (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy [including monoclonal antibodies]) [Note: Taxane exposure (maximum 6 cycles) in the adjuvant or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy]. Prior treatment with sipuleucel-T is allowed.
Any investigational agents within 28 days prior to day of randomization
Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar classes
Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy, or investigational therapy
Transfusion or use of bone marrow stimulating agents for the sole purpose of making a participant eligible for study inclusion
Patients with a history of CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with CNS metastases are eligible if received therapy (surgery, radiotherapy, gamma knife), asymptomatic and neurologically stable without corticosteroids. Participants with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired.
Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression

History or current diagnosis of the following ECG abnormalities indicating significant risk of safety for study participants:

Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
History of familial long QT syndrome or known family history of Torsades de Pointe
Cardiac or cardiac repolarization abnormality, including any of the following: History of myocardial infarction (MI), angina pectoris, or CABG within 6 months prior to starting study treatment

Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation

HIV-infected participants who are at a low risk of AIDS-related outcomes may participate in this trial.
Participants with an active documented COVID-19 infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance).
Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. Participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years prior to randomization are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer
Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF
Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: Participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.
History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
Any condition that precludes raised arms position
Presence of any mutations or biomarkers that are known to as predictors of better response to treatments other than ARDT (e.g., AR-V7 or BRCA)
Not able to understand and to comply with study instructions and requirements

Study Locations

United States
University of Florida College of Medicine x
Recruiting
Gainesville, 32610 - Florida
Contact: (352-273-7770) Robert Zlotecki
United States
Tulane University Health Sciences Center
Recruiting
New Orleans, 70112 - Louisiana
Contact: (504-988-7869) Alton Oliver Sartor
United States
Dana-Farber Cancer Institute Dana-Farber Cancer Institute_
Recruiting
Boston, 02115 - Massachusetts
Contact: Madeleine Aitken - [email protected] - Jacqueline M. Kilar (857-215-0288) - [email protected] - Xiao Wei
United States
Beth Israel Deaconess Medical Center Dept. of BIDMC
Recruiting
Boston, 02215 - Massachusetts
Contact: Glenn Bubley
United States
Washington University School of Medicine Siteman Cancer Center
Recruiting
Saint Louis, 63110 - Missouri
Contact: Dorota Grabowska (314-747-8085) - [email protected] - Brian C Baumann
United States
Urology Cancer Center PC
Recruiting
Omaha, 68130 - Nebraska
Contact: Jennifer Johnson (402-697-2229) - [email protected] - Luke Nordquist
United States
Nebraska Cancer Specialists Oncology Hematology West
Recruiting
Omaha, 68154 - Nebraska
Contact: Megan Meays (402-334-4773) - [email protected] - Ralph Hauke
United States
NYU Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center
Recruiting
New York, 10016 - New York
Contact: (212-731-6267) David Wise
United States
Duke University Medical Center Morris Building
Recruiting
Durham, 27710 - North Carolina
Contact: (919-681-6932) Daniel J. George
United States
The Ohio State University Comprehensive Cancer Center PulmonaryClinicalTrialsOffice
Recruiting
Columbus, 43221 - Ohio
Contact: Noor Matar (614-366-2361) - [email protected] - J.P. Monk
United States
Carolina Urologic Research Center, LLC
Recruiting
Myrtle Beach, 29572 - South Carolina
Contact: Jennifer Sutton (843-839-1679) - [email protected] - Neal D. Shore
United States
Sarah Cannon Research Institute
Recruiting
Nashville, 37203 - Tennessee
Contact: Sharon Rector - [email protected] - Meredith Ann McKean
United States
Texas Oncology Baylor Charles A Sammons Cancer Ctr
Recruiting
Dallas, 75246 - Texas
Contact: Jennifer Wright - [email protected] - Thomas E. Hutson
United States
University of Texas MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Sandip Chakraborty (713-792-2921) - [email protected] - Christopher Logothetis
United States
Utah Cancer Specialists UT Cancer Cnt
Recruiting
Salt Lake City, 84106 - Utah
Contact: Stephan Kendall
United States
Virginia Oncology Associates VOA - Lake Wright
Recruiting
Norfolk, 23502 - Virginia
Contact: Brittany Germain (757-213-5637) - [email protected] - Mark Fleming
United States
Oncology Hematology Associates of Southeast Virginia Roanoke Loc
Recruiting
Roanoke, 24014 - Virginia
Contact: Natasha Holt (540-982-0237) - [email protected] - David Buck
United States
Seattle Cancer Care Alliance
Recruiting
Seattle, 98105 - Washington
Contact: Kathlyn Acosta (206-288-6525) - [email protected] - Michael Schweizer
United States
University of Florida College of Medicine x
Recruiting
Gainesville, 32610 - Florida
Contact: (352-273-7770) Robert Zlotecki
United States
Tulane University Health Sciences Center
Recruiting
New Orleans, 70112 - Louisiana
Contact: (504-988-7869) Alton Oliver Sartor
United States
Dana-Farber Cancer Institute Dana-Farber Cancer Institute_
Recruiting
Boston, 02115 - Massachusetts
Contact: Madeleine Aitken - [email protected] - Jacqueline M. Kilar (857-215-0288) - [email protected] - Xiao Wei
United States
Beth Israel Deaconess Medical Center Dept. of BIDMC
Recruiting
Boston, 02215 - Massachusetts
Contact: Glenn Bubley
United States
Washington University School of Medicine Siteman Cancer Center
Recruiting
Saint Louis, 63110 - Missouri
Contact: Dorota Grabowska (314-747-8085) - [email protected] - Brian C Baumann
United States
Urology Cancer Center PC
Recruiting
Omaha, 68130 - Nebraska
Contact: Jennifer Johnson (402-697-2229) - [email protected] - Luke Nordquist
United States
Nebraska Cancer Specialists Oncology Hematology West
Recruiting
Omaha, 68154 - Nebraska
Contact: Megan Meays (402-334-4773) - [email protected] - Ralph Hauke
United States
NYU Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center
Recruiting
New York, 10016 - New York
Contact: (212-731-6267) David Wise
United States
Duke University Medical Center Morris Building
Recruiting
Durham, 27710 - North Carolina
Contact: (919-681-6932) Daniel J. George
United States
The Ohio State University Comprehensive Cancer Center PulmonaryClinicalTrialsOffice
Recruiting
Columbus, 43221 - Ohio
Contact: Noor Matar (614-366-2361) - [email protected] - J.P. Monk
United States
Carolina Urologic Research Center, LLC
Recruiting
Myrtle Beach, 29572 - South Carolina
Contact: Jennifer Sutton (843-839-1679) - [email protected] - Neal D. Shore
United States
Sarah Cannon Research Institute
Recruiting
Nashville, 37203 - Tennessee
Contact: Sharon Rector - [email protected] - Meredith Ann McKean
United States
Texas Oncology Baylor Charles A Sammons Cancer Ctr
Recruiting
Dallas, 75246 - Texas
Contact: Jennifer Wright - [email protected] - Thomas E. Hutson
United States
University of Texas MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Sandip Chakraborty (713-792-2921) - [email protected] - Christopher Logothetis
United States
Utah Cancer Specialists UT Cancer Cnt
Recruiting
Salt Lake City, 84106 - Utah
Contact: Stephan Kendall
United States
Virginia Oncology Associates VOA - Lake Wright
Recruiting
Norfolk, 23502 - Virginia
Contact: Brittany Germain (757-213-5637) - [email protected] - Mark Fleming
United States
Oncology Hematology Associates of Southeast Virginia Roanoke Loc
Recruiting
Roanoke, 24014 - Virginia
Contact: Natasha Holt (540-982-0237) - [email protected] - David Buck
United States
Seattle Cancer Care Alliance
Recruiting
Seattle, 98105 - Washington
Contact: Kathlyn Acosta (206-288-6525) - [email protected] - Michael Schweizer
United States
University of Florida College of Medicine x
Recruiting
Gainesville, 32610 - Florida
Contact: (352-273-7770) Robert Zlotecki
United States
Tulane University Health Sciences Center
Recruiting
New Orleans, 70112 - Louisiana
Contact: (504-988-7869) Alton Oliver Sartor
United States
Dana-Farber Cancer Institute Dana-Farber Cancer Institute_
Recruiting
Boston, 02115 - Massachusetts
Contact: Madeleine Aitken - [email protected] - Jacqueline M. Kilar (857-215-0288) - [email protected] - Xiao Wei
United States
Beth Israel Deaconess Medical Center Dept. of BIDMC
Recruiting
Boston, 02215 - Massachusetts
Contact: Glenn Bubley
United States
Washington University School of Medicine Siteman Cancer Center
Recruiting
Saint Louis, 63110 - Missouri
Contact: Dorota Grabowska (314-747-8085) - [email protected] - Brian C Baumann
United States
Urology Cancer Center PC
Recruiting
Omaha, 68130 - Nebraska
Contact: Jennifer Johnson (402-697-2229) - [email protected] - Luke Nordquist
United States
Nebraska Cancer Specialists Oncology Hematology West
Recruiting
Omaha, 68154 - Nebraska
Contact: Megan Meays (402-334-4773) - [email protected] - Ralph Hauke
United States
NYU Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center
Recruiting
New York, 10016 - New York
Contact: (212-731-6267) David Wise
United States
Duke University Medical Center Morris Building
Recruiting
Durham, 27710 - North Carolina
Contact: (919-681-6932) Daniel J. George
United States
The Ohio State University Comprehensive Cancer Center PulmonaryClinicalTrialsOffice
Recruiting
Columbus, 43221 - Ohio
Contact: Noor Matar (614-366-2361) - [email protected] - J.P. Monk
United States
Carolina Urologic Research Center, LLC
Recruiting
Myrtle Beach, 29572 - South Carolina
Contact: Jennifer Sutton (843-839-1679) - [email protected] - Neal D. Shore
United States
Sarah Cannon Research Institute
Recruiting
Nashville, 37203 - Tennessee
Contact: Sharon Rector - [email protected] - Meredith Ann McKean
United States
Texas Oncology Baylor Charles A Sammons Cancer Ctr
Recruiting
Dallas, 75246 - Texas
Contact: Jennifer Wright - [email protected] - Thomas E. Hutson
United States
University of Texas MD Anderson Cancer Center
Recruiting
Houston, 77030 - Texas
Contact: Sandip Chakraborty (713-792-2921) - [email protected] - Christopher Logothetis
United States
Utah Cancer Specialists UT Cancer Cnt
Recruiting
Salt Lake City, 84106 - Utah
Contact: Stephan Kendall
United States
Virginia Oncology Associates VOA - Lake Wright
Recruiting
Norfolk, 23502 - Virginia
Contact: Brittany Germain (757-213-5637) - [email protected] - Mark Fleming
United States
Oncology Hematology Associates of Southeast Virginia Roanoke Loc
Recruiting
Roanoke, 24014 - Virginia
Contact: Natasha Holt (540-982-0237) - [email protected] - David Buck
United States
Seattle Cancer Care Alliance
Recruiting
Seattle, 98105 - Washington
Contact: Kathlyn Acosta (206-288-6525) - [email protected] - Michael Schweizer
United States
Austria
Novartis Investigative Site
Recruiting
Innsbruck, 6020
Tyrol
Austria
Novartis Investigative Site
Recruiting
Linz, A-4010
-
Austria
Novartis Investigative Site
Recruiting
Wien, 1090
-
Austria
Novartis Investigative Site
Recruiting
Innsbruck, 6020
Tyrol
Austria
Novartis Investigative Site
Recruiting
Linz, A-4010
-
Austria
Novartis Investigative Site
Recruiting
Wien, 1090
-
Austria
Novartis Investigative Site
Recruiting
Innsbruck, 6020
Tyrol
Austria
Novartis Investigative Site
Recruiting
Linz, A-4010
-
Austria
Novartis Investigative Site
Recruiting
Wien, 1090
-
Austria
Belgium
Novartis Investigative Site
Recruiting
Bruxelles, 1200
-
Belgium
Novartis Investigative Site
Recruiting
Gent, 9000
-
Belgium
Novartis Investigative Site
Recruiting
Liege, 4000
-
Belgium
Novartis Investigative Site
Recruiting
Roeselare, 8800
-
Belgium
Novartis Investigative Site
Recruiting
Bruxelles, 1200
-
Belgium
Novartis Investigative Site
Recruiting
Gent, 9000
-
Belgium
Novartis Investigative Site
Recruiting
Liege, 4000
-
Belgium
Novartis Investigative Site
Recruiting
Roeselare, 8800
-
Belgium
Novartis Investigative Site
Recruiting
Bruxelles, 1200
-
Belgium
Novartis Investigative Site
Recruiting
Gent, 9000
-
Belgium
Novartis Investigative Site
Recruiting
Liege, 4000
-
Belgium
Novartis Investigative Site
Recruiting
Roeselare, 8800
-
Belgium
Czech Republic
Novartis Investigative Site
Recruiting
Olomouc, 775 20
CZE
Czech Republic
Novartis Investigative Site
Recruiting
Olomouc, 775 20
CZE
Czech Republic
Novartis Investigative Site
Recruiting
Olomouc, 775 20
CZE
Czech Republic
France
Novartis Investigative Site
Recruiting
Angers cedex 02, 49055
-
France
Novartis Investigative Site
Recruiting
Bordeaux, 33076
-
France
Novartis Investigative Site
Recruiting
Clermont-Ferrand, 63011
-
France
Novartis Investigative Site
Recruiting
Lyon Cedex, 69373
-
France
Novartis Investigative Site
Recruiting
Paris, 75970
-
France
Novartis Investigative Site
Recruiting
Villejuif Cedex, 94800
-
France
Novartis Investigative Site
Recruiting
Angers cedex 02, 49055
-
France
Novartis Investigative Site
Recruiting
Bordeaux, 33076
-
France
Novartis Investigative Site
Recruiting
Clermont-Ferrand, 63011
-
France
Novartis Investigative Site
Recruiting
Lyon Cedex, 69373
-
France
Novartis Investigative Site
Recruiting
Paris, 75970
-
France
Novartis Investigative Site
Recruiting
Villejuif Cedex, 94800
-
France
Novartis Investigative Site
Recruiting
Angers cedex 02, 49055
-
France
Novartis Investigative Site
Recruiting
Bordeaux, 33076
-
France
Novartis Investigative Site
Recruiting
Clermont-Ferrand, 63011
-
France
Novartis Investigative Site
Recruiting
Lyon Cedex, 69373
-
France
Novartis Investigative Site
Recruiting
Paris, 75970
-
France
Novartis Investigative Site
Recruiting
Villejuif Cedex, 94800
-
France
Germany
Novartis Investigative Site
Recruiting
Essen, 45147
-
Germany
Novartis Investigative Site
Recruiting
Muenchen, 80377
-
Germany
Novartis Investigative Site
Recruiting
Rostock, 18057
-
Germany
Novartis Investigative Site
Recruiting
Essen, 45147
-
Germany
Novartis Investigative Site
Recruiting
Muenchen, 80377
-
Germany
Novartis Investigative Site
Recruiting
Rostock, 18057
-
Germany
Novartis Investigative Site
Recruiting
Essen, 45147
-
Germany
Novartis Investigative Site
Recruiting
Koeln, 50937
-
Germany
Novartis Investigative Site
Recruiting
Muenchen, 80377
-
Germany
Novartis Investigative Site
Recruiting
Rostock, 18057
-
Germany
Netherlands
Novartis Investigative Site
Recruiting
Nijmegen, 6525 GA
Netherland
Netherlands
Novartis Investigative Site
Recruiting
Maastricht, 6229 HX
-
Netherlands
Novartis Investigative Site
Recruiting
Utrecht, 3584CX
-
Netherlands
Novartis Investigative Site
Recruiting
Nijmegen, 6525 GA
Netherland
Netherlands
Novartis Investigative Site
Recruiting
Maastricht, 6229 HX
-
Netherlands
Novartis Investigative Site
Recruiting
Utrecht, 3584CX
-
Netherlands
Novartis Investigative Site
Recruiting
Nijmegen, 6525 GA
Netherland
Netherlands
Novartis Investigative Site
Recruiting
Maastricht, 6229 HX
-
Netherlands
Novartis Investigative Site
Recruiting
Utrecht, 3584CX
-
Netherlands
Poland
Novartis Investigative Site
Recruiting
Gliwice, 44-101
Slaskie
Poland
Novartis Investigative Site
Recruiting
Gliwice, 44-101
Slaskie
Poland
Novartis Investigative Site
Recruiting
Gliwice, 44-101
Slaskie
Poland
Slovakia
Novartis Investigative Site
Recruiting
Bratislava, 83310
Slovak Republic
Slovakia
Novartis Investigative Site
Recruiting
Bratislava, 83310
Slovak Republic
Slovakia
Novartis Investigative Site
Recruiting
Bratislava, 83310
Slovak Republic
Slovakia
Spain
Novartis Investigative Site
Recruiting
Malaga, 29010
Andalucia
Spain
Novartis Investigative Site
Recruiting
Sevilla, 41013
Andalucia
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08035
Catalunya
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08036
Catalunya
Spain
Novartis Investigative Site
Recruiting
Hospitalet de LLobregat, 08907
Catalunya
Spain
Novartis Investigative Site
Recruiting
Valencia, 46009
Comunidad Valenciana
Spain
Novartis Investigative Site
Recruiting
Santiago de Compostela, 15706
Galicia
Spain
Novartis Investigative Site
Recruiting
El Palmar, 30120
Murcia
Spain
Novartis Investigative Site
Recruiting
Pamplona, 31008
Navarra
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28009
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28040
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28222
-
Spain
Novartis Investigative Site
Recruiting
Valencia, 46026
-
Spain
Novartis Investigative Site
Recruiting
Malaga, 29010
Andalucia
Spain
Novartis Investigative Site
Recruiting
Sevilla, 41013
Andalucia
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08035
Catalunya
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08036
Catalunya
Spain
Novartis Investigative Site
Recruiting
Hospitalet de LLobregat, 08907
Catalunya
Spain
Novartis Investigative Site
Recruiting
Valencia, 46009
Comunidad Valenciana
Spain
Novartis Investigative Site
Recruiting
Santiago de Compostela, 15706
Galicia
Spain
Novartis Investigative Site
Recruiting
El Palmar, 30120
Murcia
Spain
Novartis Investigative Site
Recruiting
Pamplona, 31008
Navarra
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28009
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28040
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28222
-
Spain
Novartis Investigative Site
Recruiting
Valencia, 46026
-
Spain
Novartis Investigative Site
Recruiting
Malaga, 29010
Andalucia
Spain
Novartis Investigative Site
Recruiting
Sevilla, 41013
Andalucia
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08035
Catalunya
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08036
Catalunya
Spain
Novartis Investigative Site
Recruiting
Hospitalet de LLobregat, 08907
Catalunya
Spain
Novartis Investigative Site
Recruiting
Valencia, 46009
Comunidad Valenciana
Spain
Novartis Investigative Site
Recruiting
Santiago de Compostela, 15706
Galicia
Spain
Novartis Investigative Site
Recruiting
El Palmar, 30120
Murcia
Spain
Novartis Investigative Site
Recruiting
Pamplona, 31008
Navarra
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28009
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28040
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28041
-
Spain
Novartis Investigative Site
Recruiting
Madrid, 28222
-
Spain
Novartis Investigative Site
Recruiting
Valencia, 46026
-
Spain
Sweden
Novartis Investigative Site
Recruiting
Goteborg, 413 45
-
Sweden
Novartis Investigative Site
Recruiting
Lund, 221 85
-
Sweden
Novartis Investigative Site
Recruiting
Stockholm, 17176
-
Sweden
Novartis Investigative Site
Recruiting
Goteborg, 413 45
-
Sweden
Novartis Investigative Site
Recruiting
Lund, 221 85
-
Sweden
Novartis Investigative Site
Recruiting
Stockholm, 17176
-
Sweden
Novartis Investigative Site
Recruiting
Goteborg, 413 45
-
Sweden
Novartis Investigative Site
Recruiting
Lund, 221 85
-
Sweden
Novartis Investigative Site
Recruiting
Stockholm, 17176
-
Sweden
Switzerland
Novartis Investigative Site
Recruiting
Baden, 5404
-
Switzerland
Novartis Investigative Site
Recruiting
Lausanne, 1011
-
Switzerland
Novartis Investigative Site
Recruiting
Zuerich, 8091
-
Switzerland
Novartis Investigative Site
Recruiting
Baden, 5404
-
Switzerland
Novartis Investigative Site
Recruiting
Lausanne, 1011
-
Switzerland
Novartis Investigative Site
Recruiting
Zuerich, 8091
-
Switzerland
Novartis Investigative Site
Recruiting
Baden, 5404
-
Switzerland
Novartis Investigative Site
Recruiting
Lausanne, 1011
-
Switzerland
Novartis Investigative Site
Recruiting
Zuerich, 8091
-
Switzerland
United Kingdom
Novartis Investigative Site
Recruiting
Guildford, GU2 7XX
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Sutton, SM2 5PT
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Middlesbrough, TS4 3BW
Yorkshire
United Kingdom
Novartis Investigative Site
Recruiting
London, EC1A 7BE
-
United Kingdom
Novartis Investigative Site
Recruiting
London, NW3 2QG
-
United Kingdom
Novartis Investigative Site
Recruiting
Guildford, GU2 7XX
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Sutton, SM2 5PT
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Middlesbrough, TS4 3BW
Yorkshire
United Kingdom
Novartis Investigative Site
Recruiting
London, EC1A 7BE
-
United Kingdom
Novartis Investigative Site
Recruiting
London, NW3 2QG
-
United Kingdom
Novartis Investigative Site
Recruiting
Guildford, GU2 7XX
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Sutton, SM2 5PT
Surrey
United Kingdom
Novartis Investigative Site
Recruiting
Middlesbrough, TS4 3BW
Yorkshire
United Kingdom
Novartis Investigative Site
Recruiting
London, EC1A 7BE
-
United Kingdom
Novartis Investigative Site
Recruiting
London, NW3 2QG
-
United Kingdom
Canada
Novartis Investigative Site
Recruiting
Montreal, H2W 1T8
Quebec
Canada

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]